Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 alterations in myeloid leukemia.

Anita Boyapati1, Eiki Kanbe, Dong-Er Zhang

  • 1Division of Oncovirology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

Acta Haematologica
|December 4, 2003
PubMed
Summary

Hematological malignancies like leukemia may develop without p53 gene mutations by inactivating critical downstream targets of the p53 tumor suppressor. This review explores p53

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction.

Nature communications·2026
Same author

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction.

bioRxiv : the preprint server for biology·2025
Same author

Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case Report.

EJHaem·2025
Same author

Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML.

Blood neoplasia·2025
Same author

GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial.

Nature communications·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Most solid tumors exhibit inactivating mutations in the p53 tumor suppressor gene.
  • Hematological malignancies, such as leukemia, rarely (<20%) show p53 gene alterations.
  • The mechanism by which these cancers develop despite a functional p53 pathway is unclear.

Purpose of the Study:

  • To investigate how hematological malignancies arise in the presence of an intact p53 tumor suppressor.
  • To explore the potential inactivation of critical p53 downstream targets in leukemia.
  • To review novel biochemical and transcriptional functions of p53 and its status in myeloid leukemias.

Main Methods:

  • Literature review of biochemical and transcriptional activities of p53.
  • Analysis of the status of p53 in acute myelogenous leukemia (AML).
  • Analysis of the status of p53 in chronic myelogenous leukemia (CML).

Main Results:

  • Evidence suggests that critical downstream targets of p53 are inactivated in leukemia.
  • This inactivation bypasses the need for direct p53 gene mutations.
  • New insights into p53's biochemical and transcriptional roles are presented.

Conclusions:

  • Leukemogenesis can occur through the disruption of p53's effector pathways, not solely through p53 mutations.
  • Understanding these alternative mechanisms is crucial for developing targeted therapies for hematological malignancies.
  • Further research into p53's functions and its targets in AML and CML is warranted.

Related Experiment Videos